-
After-Hours Movers 09/10: (LXRX) (TTOO) Higher; (ZS) (GME) (PLAY) Lower (more...)
-
Sanofi successfully prices EUR 8 billion of bond issues
-
Sanofi successfully prices EUR 8 billion of bond issues
-
Sanofi successfully prices EUR 8 billion of bond issues
-
Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...)
-
3 Key Takeaways as Medivation (MDVN) Enters Next Phase of Takeover Talks
-
Notable Analyst Rating Changes 5/3: (MEP) (RSG) (AXTI) Upgraded; (CYH) (UTX) (SRPT) Downgraded
-
Amgen (AMGN) Patent Wins Increase Likelihood of Settlement, Says RBC
-
MannKind's (MNKD) Options Could Be Limited Following Termination of Afrezza Collaboration with Sanofi (SNY), Says RBC
-
MannKind's (MNKD) Price Target Reduced to $9 at RBC, Outperform Rating Maintained
-
Dyax Corp (DYAX) Gains on Takeover Speculation
-
RBC Capital Comments on Regeneron (REGN) Following 'Unexpectedly Cautious' Adcom
-
Sanofi (SNY) 'Seemingly Committed' to MannKind's (MNKD) Afrezza, RBC Says; 2nd-Half Efforts to Focus on Awareness
-
FDA Breifing Documents for Regeneron's (REGN) Praluent 'Read Well,' Says RBC Capital
-
Amgen (AMGN) Suit No Surprise for Regeneron (REGN) - Analyst (SNY)
-
MannKind (MNKD): RBC Updates Model to Reflect Deal with Sanofi, Lowers PT
-
MannKind (MNKD)/Sanofi (SNY) Deal Seen as Solid Positive at RBC
-
Pre-Open Stock Movers 9/9: (MOLX) (UNIS) (ISIS) Higher; (BIOD) (HSOL) (SCTY) Lower (more...)
-
Notable 52-Week Highs and Lows of the Day 04/03: (FNP) (ASTX) (SNY) High; (X) (AKS) (STSI) Low
-
Notable Analyst Rating Changes 05/10: (TPX) (PRU) (KERX) Upgraded; (VRTX) (HGSI) (ORCL) Downgraded
-
Notable Mergers and Acquisitions of the Day 07/11: (ARJ) (BTU)/(MT) (VRX)/(SNY) (SWC)
-
Notable Analyst Rating Changes 4/30: OXPS, SNY, LAMR Upgraded; SQNM, GT, ITRI Downgraded
-
Notable Analyst Rating Changes 1/26: LEN, GRMN, LUV, PETM, LEAP Upgraded; BHP, BAC, USB, AFL, ENR Downgraded

